journal
MENU ▼
Read by QxMD icon Read
search

Annals of Oncology: Official Journal of the European Society for Medical Oncology

journal
https://www.readbyqxmd.com/read/28449055/primary-tumor-sidedness-has-an-impact-on-prognosis-and-treatment-outcome-in-metastatic-colorectal-cancer-results-from-two-randomized-first-line-panitumumab-studies
#1
N Boeckx, R Koukakis, K Op de Beeck, C Rolfo, G Van Camp, S Siena, J Tabernero, J-Y Douillard, T André, M Peeters
Background: : Previous studies have reported the prognostic impact of primary tumor sidedness in metastatic colorectal cancer (mCRC) and its influence on cetuximab efficacy. The present retrospective analysis of two panitumumab trials investigated a possible association between tumor sidedness and treatment efficacy in first-line mCRC patients with RAS wild-type (WT) primary tumors. Material and methods: Data from two randomized first-line panitumumab trials were analyzed for treatment outcomes by primary tumor sidedness for RAS WT patients...
April 25, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28449049/professional-burnout-in-european-young-oncologists-results-of-the-european-society-for-medical-oncology-esmo-young-oncologists-committee-burnout-survey
#2
S Banerjee, R Califano, J Corral, E de Azambuja, L De Mattos-Arruda, V Guarneri, M Hutka, K Jordan, E Martinelli, G Mountzios, M A Ozturk, M Petrova, S Postel-Vinay, M Preusser, C Qvortrup, M N M Volkov, J Tabernero, D Olmos, M H Strijbos
Background: Burnout in health care professionals could have serious negative consequences on quality of patient care, professional satisfaction and personal life. Our aim was to investigate the burnout prevalence, work and lifestyle factors potentially affecting burnout amongst European oncologists ≤40 (YOs). Methods: A survey was conducted using the validated Maslach Burnout Inventory (MBI) and additional questions exploring work/lifestyle factors. Statistical analyses were performed to identify factors associated with burnout...
April 25, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28444131/fulvestrant-plus-lhrh-analogs-in-male-with-synchronous-breast-and-prostate-cancer
#3
C Martinez, L A Fernández-Morales, H Oliveres, M Marín, P Ribera, J C Pardo, E Dalmau, M A Segui
No abstract text is available yet for this article.
April 24, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28444114/efficacy-of-everolimus-plus-octreotide-lar-in-patients-with-advanced-neuroendocrine-tumor-and-carcinoid-syndrome-final-overall-survival-from-the-randomized-placebo-controlled-phase-3-radiant-2-study
#4
M E Pavel, E Baudin, K E Öberg, J D Hainsworth, M Voi, N Rouyrre, M Peeters, D J Gross, J C Yao
Background: In the phase 3 RADIANT-2 study, everolimus plus octreotide long-acting repeatable (LAR) showed improvement of 5.1 months in median progression-free survival vs placebo plus octreotide LAR among patients with advanced neuroendocrine tumors associated with carcinoid syndrome. The progression-free survival P-value was marginally above the prespecified threshold for statistical significance. Here, we report final overall survival (OS) and key safety update from RADIANT-2. Patients and methods: The RADIANT-2 trial compared everolimus (10 mg/day, orally; n= 216) vs placebo ( n= 213), both in conjunction with octreotide LAR (30 mg, intramuscularly, every 28 days)...
April 24, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28444115/assessing-treatment-efficacy-in-the-subset-of-responders-in-a-randomized-clinical-trial
#5
E L Korn, M Othus, T Chen, B Freidlin
Background: Durability of response is a clinically relevant dimension of the treatment effect in randomized clinical trials; it is often measured by comparing among the responders the duration of response between the treatment arms. However, since the comparison groups are defined by response (a post-randomization event), it is subject to analysis-by-responder bias, especially if the proportion of responders differs between the arms. Methods: Two simple methods are developed that use tumor shrinkage measurements in order to lessen analysis-by-responder bias by generating more comparable patient subsets in the control and experimental arms of the trial...
April 21, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28444112/incidence-course-and-management-of-toxicities-associated-with-cobimetinib-in-combination-with-vemurafenib-in-the-cobrim-study
#6
B Dréno, A Ribas, J Larkin, P A Ascierto, A Hauschild, L Thomas, J-J Grob, D O Koralek, I Rooney, J J Hsu, E F McKenna, G A McArthur
The combination of cobimetinib plus vemurafenib is well tolerated in patients with advanced BRAFV600-mutated melanomaAEs generally occur early and are manageable through patient monitoring, dose modification, and supportive careThe favourable safety profile and significantly improved patient outcomes support the use of cobimetinib plus vemurafenib as a standard of care for initial treatment.
April 21, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28444111/pattern-recognition-receptors-immune-targets-to-enhance-cancer-immunotherapy
#7
T Shekarian, S Valsesia-Wittmann, J Brody, M C Michallet, S Depil, C Caux, A Marabelle
Durable tumor responses and significant levels of disease control rates have been described in more than 20 advanced/metastatic cancer types with B7-family immune checkpoint-targeted anti-CTLA-4, anti-PD-1, and anti-PD-L1 monoclonal antibodies. These results and the recent approvals of ipilimumab, pembrolizumab, nivolumab and atezolizumab are currently revolutionizing the way we envision the future of cancer care. However these clinical benefits are not observed in all cancer types and in every patient. Therefore, our clinical challenge is to identify therapeutic strategies which could overcome the primary and secondary resistances to these novel cancer immunotherapies...
April 21, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28444105/clinical-pathological-and-demographic-factors-associated-with-development-of-recurrences-after-surgical-resection-in-elderly-patients-with-neuroendocrine-tumors
#8
C Shen, A Dasari, Y Chu, D M Halperin, S Zhou, Y Xu, Y T Shih, J C Yao
Background: Incidence of locoregional neuroendocrine tumors (NETs) is rising. However, after curative resection, the patterns and risk factors associated with recurrence remain unknown. Consensus guidelines recommend surveillance every 6-12 months for up to 10 years after surgery for resected, well-differentiated NETs irrespective of patient demographics, site, grade or stage of tumor with few exceptions. Patients and Methods: From the Surveillance, Epidemiology and End Results (SEER)-Medicare database, we identified localized and regional stage NET patients who underwent surgical resection between 1/2002 and 12/2011...
April 21, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28430888/qol-is-a-cool-tool
#9
L Procaccio, S Lonardi, F Loupakis, M Di Maio
No abstract text is available yet for this article.
April 18, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28430865/unmet-needs-in-the-first-line-treatment-of-follicular-lymphoma
#10
C Casulo, L Nastoupil, N H Fowler, J W Friedberg, C R Flowers
For the majority of patients with newly diagnosed follicular lymphoma (FL), current treatments, while not curative, allow for long remission durations. However, several important needs remain unaddressed. Studies have consistently shown that approximately 20% of patients with FL experience disease progression within 2 years of first-line treatment, and consequently have a 50% risk of death in 5 years. Better characterization of this group of patients at diagnosis may provide insight into those in need of alternate or intensive therapies, facilitate a precision approach to inform clinical trials, and allow for improved patient counseling...
April 18, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28430863/fgfr2-amplification-in-metastatic-hormone-positive-breast-cancer-and-response-to-an-mtor-inhibitor
#11
Lironne Wein, Peter Savas, Courtney Van Geelan, Franco Caramia, Kate Moodie, Sachin Joshi, Sherene Loi
No abstract text is available yet for this article.
April 18, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28430862/how-health-related-quality-of-life-assessment-should-be-used-in-advanced-colorectal-cancer-clinical-trials
#12
F Bonnetain, C Borg, R R Adams, J A Ajani, A Benson, H Bleiberg, B Chibaudel, E Diaz-Rubio, J Y Douillard, C S Fuchs, B J Giantonio, R Goldberg, V Heinemann, M Koopman, R Labianca, A K Larsen, T Maughan, E Mitchell, M Peeters, C J A Punt, H J Schmoll, C Tournigand, A de Gramont
Traditionally, the efficacy of cancer treatment in patients with advance or metastatic disease in clinical studies has been studied using overall survival (OS) and more recently tumor-based endpoints such as progression-free survival, measurements of response to treatment. However, these seem not to be the relevant clinical endpoints in current situation if such endpoints were no validated as surrogate of OS to demonstrate the clinical efficacy. Appropriate, meaningful, primary patient-oriented and patient-reported endpoints that adequately measure the effects of new therapeutic interventions are then crucial for the advancement of clinical research in metastatic colorectal cancer to complement the results of tumor-based endpoints...
April 18, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28430861/reply-to-the-letter-to-the-editor-addressing-the-quality-of-the-esmo-mcbs-by-del-paggio
#13
N I Cherny, U Dafni, J Bogaerts, G Pentheroudakis, J Tabernero, C Zielinski, E G E de Vries
No abstract text is available yet for this article.
April 18, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28430855/cancer-immunotherapy-trial-registrations-increase-exponentially-but-chronic-immunosuppressive-glucocorticoid-therapy-may-compromise-outcomes
#14
C M Connell, S Raby, I Beh, T Flint, E Williams, D T Fearon, D I Jodrell, T Janowitz
No abstract text is available yet for this article.
April 14, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28419195/plasma-ctdna-ras-mutation-analysis-for-the-diagnosis-and-treatment-monitoring-of-metastatic-colorectal-cancer-patients
#15
J Vidal, L Muinelo, A Dalmases, F Jones, D Edelstein, M Iglesias, M Orrillo, A Abalo, C Rodríguez, E Brozos, Y Vidal, S Candamio, F Vázquez, J Ruiz, M Guix, L Visa, V Sikri, J Albanell, B Bellosillo, R López, C Montagut
Background: RAS assessement is mandatory for therapy decision in metastatic colorectal cancer (mCRC) patients. This determination is based on tumor tissue, however genotyping of circulating tumor (ct)DNA offers clear advantages as a minimally invasive method that represents tumor heterogeneity. Our study aims to evaluate the use of ctDNA as an alternative determining baseline RAS status and subsequent monitoring of RAS mutations during therapy as a component of routine clinical practice...
April 13, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28419193/a-randomized-phase-ii-iii-study-of-cabazitaxel-versus-vinflunine-in-metastatic-or-locally-advanced-transitional-cell-carcinoma-of-the-urothelium-secavin
#16
J Bellmunt, J M Kerst, F Vázquez, R Morales-Barrera, E Grande, A Medina, Mªb González Graguera, G Rubio, U Anido, O Fernández Calvo, E González-Billalabeitia, Ajm Van den Eertwegh, E Pujol, J L Perez-Gracia, J L González Larriba, R Collado, M Los, S Maciá, R De Wit
BACKGROUND: Despite the advent of immunotherapy in urothelial cancer, there is still a need to find effective cytotoxic agents beyond first and second line. Vinflunine is the only treatment approved in this setting by the European Medicines Agency (EMA) and taxanes are also widely used in second line. Cabazitaxel is a taxane with activity in docetaxel-refractory cancers. A randomized study was conducted to compare its efficacy vs vinflunine. PATIENTS AND METHODS: This is a multicenter, randomized, open-label, phase II/III study, following a Simon's optimal method with stopping rules based on an interim futility analysis and a formal efficacy analysis at the end of the phase II...
April 13, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28419187/kaposi-sarcoma-in-a-patient-treated-with-ruxolitinib
#17
G G Loscocco, M Vannucchi, C Paoli, A Franci, L Pieri, F Annunziato, D Massi, A M Vannucchi
No abstract text is available yet for this article.
April 13, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28419182/molecular-classification-of-pulmonary-sarcomatoid-carcinomas-suggests-new-therapeutic-opportunities
#18
N Pécuchet, T Vieira, N Rabbe, M Antoine, H Blons, J Cadranel, P Laurent-Puig, M Wislez
Background: Pulmonary sarcomatoid carcinoma (SC) is a rare disease with poor prognosis and with strong inter- and intratumor heterogeneity. However, molecular classification is currently focused on activating MET mutations. We sought to better characterize the molecular diversity of SC using mutational signatures that reflect different mutational processes, such as tobacco-associated adducts (signature 4), BRCA1/BRCA2 deficiency (signature 3) or APOBEC enzyme deamination (signatures 2&13)...
April 13, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28419181/hyperprogression-during-anti-pd-1-pd-l1-therapy-in-patients-with-recurrent-and-or-metastatic-head-and-neck-squamous-cell-carcinoma
#19
E Saâda-Bouzid, C Defaucheux, A Karabajakian, V Palomar Coloma, V Servois, X Paoletti, C Even, J Fayette, J Guigay, D Loirat, F Peyrade, M Alt, J Gal, C Le Tourneau
Background: HASH(0x2f78988) Pembrolizumab and nivolumab are immune checkpoint inhibitors targeting PD-1 that have recently been approved in pretreated recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients. In the clinic, some patients seem not only not to benefit from anti-PD-L1/PD-1 agents but rather to experience an acceleration of tumor growth kinetics (TGK). Patients and Methods: HASH(0x3021d00) We retrospectively compared TGK on immunotherapy and TGK on last treatment in patients with R/M HNSCC treated with PD-1/PD-L1 inhibitors in four French centers...
April 13, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28419178/acquiring-evidence-for-precision-prostate-cancer-care
#20
Joaquin Mateo, Suzanne Carreira, Johann S de Bono
No abstract text is available yet for this article.
April 13, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
journal
journal
30452
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"